Mirum Pharmaceuticals (MIRM) Q4 FY25 earnings call

Mirum Pharmaceuticals concluded FY25 with robust net product sales growth, driven by LIVMARLI and bile acid medicines, and provided confident 2026 guidance. The company significantly advanced its pipeline, notably with the Brelovitug acquisition and multiple near-term registrational readouts for Volixibat and LIVMARLI, positioning it for a pivotal growth phase. While R&D investments are increasing for pipeline advancement, the company maintains a strong financial position.